Cecilie Bay-Richter1, Klas R Linderholm2, Chai K Lim3, Martin Samuelsson4, Lil Träskman-Bendz5, Gilles J Guillemin3, Sophie Erhardt2, Lena Brundin6. 1. Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark. Electronic address: cbr@clin.au.dk. 2. Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden. 3. Neuroinflammation Group, Australian School of Advanced Medicine, Macquarie University, NSW, Australia. 4. Faculty of Health Sciences, Department of Clinical and Experimental Medicine, Division of Psychiatry, Linköping University, Linköping, Sweden. 5. Department of Clinical Sciences, Section of Psychiatry, Lund University, Lund, Sweden. 6. Division of Psychiatry and Behavioral Medicine, Michigan State University, Grand Rapids, MI, USA; Laboratory of Behavioral Medicine, Van Andel Research Institute, Grand Rapids, MI, USA.
Abstract
BACKGROUND: Patients with depression and suicidality suffer from low-grade neuroinflammation. Pro-inflammatory cytokines activate indoleamine 2,3-dioxygenase, an initial enzyme of the kynurenine pathway. This pathway produces neuroactive metabolites, including quinolinic- and kynurenic acid, binding to the glutamate N-methyl-d-aspartate-receptor, which is hypothesized to be part of the neural mechanisms underlying symptoms of depression. We therefore hypothesized that symptoms of depression and suicidality would fluctuate over time in patients prone to suicidal behavior, depending on the degree of inflammation and kynurenine metabolite levels in the cerebrospinal fluid (CSF). METHODS: We measured cytokines and kynurenine metabolites in CSF, collected from suicide attempters at repeated occasions over 2 years (total patient samples n=143, individuals n=30) and healthy controls (n=36). The association between the markers and psychiatric symptoms was assessed using the Montgomery Asberg Depression Rating Scale and the Suicide Assessment Scale. RESULTS: Quinolinic acid was increased and kynurenic acid decreased over time in suicidal patients versus healthy controls. Furthermore, we found a significant association between low kynurenic acid and severe depressive symptoms, as well as between high interleukin-6 levels and more severe suicidal symptoms. CONCLUSIONS: We demonstrate a long-term dysregulation of the kynurenine pathway in the central nervous system of suicide attempters. An increased load of inflammatory cytokines was coupled to more severe symptoms. We therefore suggest that patients with a dysregulated kynurenine pathway are vulnerable to develop depressive symptoms upon inflammatory conditions, as a result the excess production of the NMDA-receptor agonist quinolinic acid. This study provides a neurobiological framework supporting the use of NMDA-receptor antagonists in the treatment of suicidality and depression.
BACKGROUND:Patients with depression and suicidality suffer from low-grade neuroinflammation. Pro-inflammatory cytokines activate indoleamine 2,3-dioxygenase, an initial enzyme of the kynurenine pathway. This pathway produces neuroactive metabolites, including quinolinic- and kynurenic acid, binding to the glutamate N-methyl-d-aspartate-receptor, which is hypothesized to be part of the neural mechanisms underlying symptoms of depression. We therefore hypothesized that symptoms of depression and suicidality would fluctuate over time in patients prone to suicidal behavior, depending on the degree of inflammation and kynurenine metabolite levels in the cerebrospinal fluid (CSF). METHODS: We measured cytokines and kynurenine metabolites in CSF, collected from suicide attempters at repeated occasions over 2 years (total patient samples n=143, individuals n=30) and healthy controls (n=36). The association between the markers and psychiatric symptoms was assessed using the Montgomery Asberg Depression Rating Scale and the Suicide Assessment Scale. RESULTS:Quinolinic acid was increased and kynurenic acid decreased over time in suicidal patients versus healthy controls. Furthermore, we found a significant association between low kynurenic acid and severe depressive symptoms, as well as between high interleukin-6 levels and more severe suicidal symptoms. CONCLUSIONS: We demonstrate a long-term dysregulation of the kynurenine pathway in the central nervous system of suicide attempters. An increased load of inflammatory cytokines was coupled to more severe symptoms. We therefore suggest that patients with a dysregulated kynurenine pathway are vulnerable to develop depressive symptoms upon inflammatory conditions, as a result the excess production of the NMDA-receptor agonist quinolinic acid. This study provides a neurobiological framework supporting the use of NMDA-receptor antagonists in the treatment of suicidality and depression.
Authors: Philippe Leff-Gelman; Ismael Mancilla-Herrera; Mónica Flores-Ramos; Carlos Cruz-Fuentes; Juan Pablo Reyes-Grajeda; María Del Pilar García-Cuétara; Marielle Danitza Bugnot-Pérez; David Ellioth Pulido-Ascencio Journal: Neurosci Bull Date: 2016-07-18 Impact factor: 5.203
Authors: Zuleide M Ignácio; Renato S da Silva; Marcos E Plissari; João Quevedo; Gislaine Z Réus Journal: Mol Neurobiol Date: 2019-06-21 Impact factor: 5.590
Authors: Hyong Jin Cho; Jonathan Savitz; Robert Dantzer; T Kent Teague; Wayne C Drevets; Michael R Irwin Journal: J Psychosom Res Date: 2017-05-22 Impact factor: 3.006
Authors: Abhishek Wadhawan; Aline Dagdag; Allyson Duffy; Melanie L Daue; Kathy A Ryan; Lisa A Brenner; John W Stiller; Toni I Pollin; Maureen W Groer; Xuemei Huang; Christopher A Lowry; Braxton D Mitchell; Teodor T Postolache Journal: Pteridines Date: 2017-11-22 Impact factor: 0.581
Authors: M K Larsson; A Faka; M Bhat; S Imbeault; M Goiny; F Orhan; A Oliveros; S Ståhl; X C Liu; D S Choi; K Sandberg; G Engberg; L Schwieler; S Erhardt Journal: Neurochem Res Date: 2016-05-10 Impact factor: 3.996
Authors: Geoffroy Laumet; Wenjun Zhou; Robert Dantzer; Jules D Edralin; XiaoJiao Huo; David P Budac; Jason C O'Connor; Anna W Lee; Cobi J Heijnen; Annemieke Kavelaars Journal: Brain Behav Immun Date: 2017-07-11 Impact factor: 7.217
Authors: Gislaine Z Réus; Karen Jansen; Stephanie Titus; André F Carvalho; Vilma Gabbay; João Quevedo Journal: J Psychiatr Res Date: 2015-05-19 Impact factor: 4.791
Authors: Timothy B Meier; Wayne C Drevets; T Kent Teague; Brent E Wurfel; Sven C Mueller; Jerzy Bodurka; Robert Dantzer; Jonathan Savitz Journal: Brain Behav Immun Date: 2017-09-01 Impact factor: 7.217
Authors: Timothy B Meier; Jonathan Savitz; Rashmi Singh; T Kent Teague; Patrick S F Bellgowan Journal: J Neurotrauma Date: 2016-01-13 Impact factor: 5.269